Bates-White Report: CPI-Based Medicaid Rebates Harm Generic Competition | Association for Accessible Medicines
AAM Statement - President Trump’s Blueprint to Lower Drug Prices

Bates-White Report: CPI-Based Medicaid Rebates Harm Generic Competition

As a way of assessing the potential future impact of the CPI-based Medicaid Generics Penalty, Bates-White Economic Consulting examined publicly available data on historical drug prices and performed calculations of the potential impact of CPI-based rebates had they been in place in the past. This report shows evidence to suggest that in certain cases, these price regulations may have precisely the opposite of their intended effect. The imposition of penalties is likely to reduce competition in generic drug markets, lead to fewer companies competing in the market, and increase the likelihood of shortages.

View Report

Issues

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.